Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.62 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.62 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.62 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.88 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.64 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phthalic Acid SCHEMBL27902559 | 0.97 | ALDH1A1 (0.93) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL2379962 | 0.97 | ALDH1A1 (0.93) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL2380964 | 0.97 | ALDH1A1 (0.93) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL4168570 | 0.94 | ALDH1A1 (0.78) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL10395162 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL588314 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL20503446 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL20503467 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL4095357 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E | |
| Phthalic Acid SCHEMBL2326168 | 0.94 | ALDH1A1 (0.88) | ALDH1A1ALOX15AKR1C3NAPRTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116516433-B | Green rapid preparation method of metal organic framework compound film coating | 中国科学院深圳先进技术研究院 | 2024-04-26 | — | — | CN | claimed |
| CN-116516433-A | Green rapid preparation method of metal organic framework compound film coating | 中国科学院深圳先进技术研究院 | 2023-08-01 | — | — | CN | claimed |
| WO-2023138283-A1 | ENVIRONMENTALLY FRIENDLY AND RAPID PREPARATION METHOD FOR METAL-ORGANIC FRAMEWORK COMPOUND THIN FILM PLATING | 中国科学院深圳先进技术研究院 | 2023-07-27 | — | — | WO | claimed |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-18 | — | — | US | claimed |
| US-20180327550-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2018-11-15 | — | — | US | claimed |
| EP-3377560-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | University of Maryland, College Park (US) | 2018-09-26 | — | — | EP | claimed |
| US-20130184499-A1 | PREPARATION OF CATALYST FOR SELECTIVE HYDROGENATION OF HYDROGENATABLE PRECURSORS | BIOAMBER INTERNATIONAL S.A.R.L. (LU) | 2013-07-18 | — | — | US | claimed |
| WO-2013106519-A1 | PREPARATION OF CATALYST FOR SELECTIVE HYDROGENATION OF HYDROGENATABLE PRECURSORS | BIOAMBER INTERNATIONAL S.A.R.L. (LU) | 2013-07-18 | — | — | WO | claimed |
| US-20260077088-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | CRANNMED LIMITED (IE) | 2026-03-19 | — | — | US | disclosed |
| US-20260053152-A1 | COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR | SAVE FOODS LTD. (IL) | 2026-02-26 | — | — | US | disclosed |
| US-12527331-B2 | Compositions and methods of treating edible matter and substrates therefor | SAVE FOODS LTD. (IL) | 2026-01-20 | — | — | US | disclosed |
| US-12465600-B2 | Pediatric suspension formulation | Xeolas Pharmaceuticals Ltd. (IE) | 2025-11-11 | — | — | US | disclosed |
| EP-4631533-A1 | ALGINATE BASED PARTICLES AS A TEMPORARY EMBOLIC AGENT | Crannmed Limited (IE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4583839-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | Crannmed Limited (IE) | 2025-07-16 | — | — | EP | disclosed |
| EP-1885333-B1 | PHARMACEUTICAL FORMULATION OF APOMORPHINE FOR BUCCAL ADMINISTRATION | AMARIN PHARMACEUTICALS IE LTD (IE) | 2012-02-15 | — | — | EP | disclosed |
| US-20090023766-A1 | Pharmaceutical formulation of apomorphine for buccal administration | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2009-01-22 | — | — | US | disclosed |
| EP-1885333-A1 | PHARMACEUTICAL FORMULATION OF APOMORPHINE FOR BUCCAL ADMINISTRATION | Amarin Pharmaceuticals Ireland Limited (IE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006120412-A1 | PHARMACEUTICAL FORMULATION OF APOMORPHINE FOR BUCCAL ADMINISTRATION | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2006-11-16 | — | — | WO | disclosed |
| US-20050227225-A1 | Stabilization of biomolecules in samples | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1584923-A2 | Stabilization of biomolecules in samples | Roche Diagnostics GmbH (DE) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327550-A1 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | PHOSPHO1, PLCG2, PLCG1 | CA12 154/4885CA1 299/4885CA2 384/4885 |
| US-11472927-B2 | Polyphosphazenes, methods of making, and uses thereof | PHOSPHO1, PLCG2, PLCG1 | CA12 154/4885CA1 299/4885CA2 384/4885 |
| US-20260053152-A1 | COMPOSITIONS AND METHODS OF TREATING EDIBLE MATTER AND SUBSTRATES THEREFOR | SOAT2, AGL, SOAT1 | CA12 623/4885CA1 715/4885CA2 167/4885 |
| US-12527331-B2 | Compositions and methods of treating edible matter and substrates therefor | AGL, SOAT2, SOAT1 | CA12 581/4885CA1 464/4885CA2 137/4885 |
| US-20090023766-A1 | Pharmaceutical formulation of apomorphine for buccal administration | PARK7, SNCA, AMY2A | CA12 1787/4885CA1 2008/4885CA2 1164/4885 |
| US-20260077088-A1 | SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES | MMP2, PLG, PMM2 | CA12 273/4885CA1 116/4885CA2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.